Search IPOs
SAIPARENT · NSE,BSE · Pharmaceutical Formulations
Sai Parenteral's IPO listed on 02 Apr 2026 on NSE,BSE at ₹400.00, a gain of 2.04% over the issue price of ₹392.00. The IPO was subscribed 1.08x overall.
Sai Parenteral's IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 24 Mar 2026 |
| IPO Close Date | 27 Mar 2026 |
| Basis of Allotment | 30 Mar 2026 |
| Initiation of Refunds | 01 Apr 2026 |
| Credit of Shares to Demat | 01 Apr 2026 |
| Listing Date | 02 Apr 2026 |
Listing day gain
+2.04%
Listed at ₹400 (issue ₹392)
Issue
₹392
Listing
₹400
Current
₹405.7
+3.49% vs issue
Day range
₹400 – ₹416
Issue Size
10,428,288 shares
(aggregating up to ₹409.00 Cr)
Issue Price
₹372 – ₹392
Face Value
₹5/share
Market Lot
38 shares
Retail Min Investment
₹14,896
Listing At
NSE,BSE
Sale Type
both
Fresh Issue
7,270,408 shares
(aggregating up to ₹285 Cr)
Offer for Sale
3,157,880 shares
(aggregating up to ₹124 Cr)
Issue Type
book building
Open Date
24 Mar
Close Date
27 Mar
Allotment
30 Mar
Listing
02 Apr
Last updated: 6 months ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 02 Apr 2026 Latest | ₹392 | ₹0 | ₹392 | ₹0 |
0%
|
12:56 PM |
| 01 Apr 2026 | ₹392 | ₹0 | ₹392 | ₹0 |
0%
|
1:07 PM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 27 Mar 2026
| Category | Subscribed (x) |
|---|---|
| QIB | 1.73x |
| NII | 2.45x |
| bNII (bids above ₹10L) | 3.56x |
| sNII (bids below ₹10L) | 0.24x |
| Retail Investors | 0.12x |
| Total | 1.08x |
Showing the latest subscription snapshot.
View full subscription historyAnil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna are the promoters of the Company.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,896 |
| Retail (Max) | 13 | 494 | ₹193,648 |
| S-HNI (Min) | 14 | 532 | ₹208,544 |
| S-HNI (Max) | 67 | 2,546 | ₹998,032 |
| B-HNI (Min) | 68 | 2,584 | ₹1,012,928 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 5,214,144 (50.00%) |
|
•
Anchor Investor Shares Offered
|
3,128,485 (30.00%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
2,085,659 (20.00%) |
| NII (HNI) Shares Offered | 1,564,243 (15.00%) |
|
•
bNII > ₹10L
|
1,042,829 (10.00%) |
|
•
sNII < ₹10L
|
521,414 (5.00%) |
| Retail Shares Offered | 3,649,901 (35.00%) |
| Total Shares Offered | 10,428,288 (100.00%) |
Sai Parenterals is a Hyderabad-based pharmaceutical company that makes various medicines like injections, tablets, and syrups. They work in two main areas: selling their own branded generic medicines and making products for other big pharma companies (CDMO). They serve government agencies, private hospitals, and also export to international markets like Australia and Southeast Asia.
Strengths:
The company has a very strong and diverse manufacturing base with five operational facilities, including internationally accredited units (TGA-Australia and WHO-GMP). This allows them to produce high-quality medicines for both Indian and global markets. Their product range is vast, covering critical areas like heart health, diabetes, and respiratory care. Financially, they have shown impressive efficiency, with their Profit After Tax (PAT) growing by 71% in just one year (FY24 to FY25) and maintaining a high EBITDA margin of over 24%, which shows strong operational health.
Growth:
Sai Parenterals is focused on aggressive expansion. A major part of the IPO funds (₹110.80 Cr) is dedicated to upgrading and expanding their factories. They are also investing heavily in R&D by setting up a new research center. Internationally, they are growing through strategic moves, such as the proposed acquisition of Noumed Pharmaceuticals in Australia. This shift from a domestic player to a global exporter, combined with their entry into regulated markets, positions them for significant future revenue growth.
Standalone · ₹ in Crores
| Particulars | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Total Revenue | 97.03 | 155.18 | 163.74 |
| Profit After Tax (PAT) | 4.38 | 8.42 | 14.43 |
| EBITDA | 17.64 | 31.7 | 39.44 |
| Total Assets | 133.96 | 268.1 | 272.39 |
| Net Worth | 31.49 | 76.4 | 95.78 |
| Reserves & Surplus | 24.34 | 61.3 | 80.36 |
| Total Borrowing | 68.55 | 118.79 | 93.95 |
Revenue & Profit Trend
The basis of allotment for Sai Parenteral's IPO was finalised on 30 Mar 2026. You can check your allotment status using your PAN number or application number on the Bigshare Services Private Limited portal or BSE.
The Sai Parenteral's IPO is expected to open in Mar 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Sai Parenteral's IPO is ₹372.00 - ₹392.00 per share.
As per market sources, Sai Parenteral's IPO GMP is currently ₹0.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Sai Parenteral's IPO stands at 1.08x overall.
The listing date for Sai Parenteral's IPO is 02 Apr 2026.
No comments yet. Be the first to comment!
